The specialty chemicals company Lanxess has successfully placed a 6-year-tenor euro benchmark bond with a coupon of 0.0 percent in the European capital market. Lanxess will use the funds to finance the planned acquisition of the microbial control business of US-based chemical company IFF. The new bond is listed on the Luxembourg Stock Exchange in denominations of EUR 1,000. “We have secured the first step of financing already quickly after the announcement of the acquisition of IFF Microbial Control and are happy about the very receptive reaction of the capital market to our offering,” said Lanxess Chief Financial Officer Michael Pontzen. Lanxess issuer ratings are currently Baa2 (Moody’s), BBB (Standard & Poor’s) and BBB+ (Scope). A bank consortium of active joint book-runners comprising Citi, Société Générale and Unicredit was mandated to place the bond. Lanxess is a leading specialty chemicals company.
This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third-party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development, or performance of Lanxess AG to differ materially from the estimations expressed or implied herein. Lanxess AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of Lanxess AG or any of its affiliated companies or any of such person officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.
For more details: www.lanxess.com
